Medium and Long-Term Outcomes After Bilateral Pulmonary Artery Stenting in Children and Adults With Congenital Heart Disease

2012 ◽  
Vol 34 (1) ◽  
pp. 179-184 ◽  
Author(s):  
Ismael Gonzalez ◽  
Damien Kenny ◽  
Shari Slyder ◽  
Ziyad M. Hijazi
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Pulmonary Artery ◽  
Congenital Heart ◽  
Long Term Outcomes

Long-term outcomes of intraoperative pulmonary artery stent placement for congenital heart disease

2010 ◽  
Vol 77 (3) ◽  
pp. 395-399 ◽  
Author(s):  
Michael J. Angtuaco ◽  
Ritu Sachdeva ◽  
Robert D.B. Jaquiss ◽  
W. Robert Morrow ◽  
Jeffrey M. Gossett ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Pulmonary Artery ◽  
Stent Placement ◽  
Congenital Heart ◽  
Long Term Outcomes

Long-term outcomes of right ventricle-to-pulmonary artery conduit insertion in adults with congenital heart disease: survival analysis by National Death Index

2021 ◽  
Author(s):  
Amalan Thuraisingam ◽  
Peter Skillington ◽  
Prakash Ludhani ◽  
Pasangi Madhuka Wijayarathne ◽  
Samuel Menahem ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Pulmonary Artery ◽  
Right Ventricle ◽  
Congenital Heart ◽  
Survival Function ◽  
Interquartile Range ◽  
National Death Index ◽  
Long Term Outcomes

Abstract OBJECTIVES The aim of this study was to investigate the long-term outcomes following right ventricle-to-pulmonary artery (RV-to-PA) conduit insertion of Medtronic Freestyle® porcine valve (MFV) or pulmonary allograft valve (PAV) in adult patients with congenital heart disease. METHODS Retrospective medical record review of consecutive RV-to-PA conduit insertion, using either PAV or MFV from 1991 to 2017. Perioperative data and clinic reports were collected. Cause and date of death were obtained from the Australian National Death Index to obtain survival function. RESULTS In total, 232 patients (median age 31.5 years, interquartile range 25–41 years) underwent RV-to-PA conduit insertion (PAV = 84 and MFV = 148) and were eligible for inclusion [63.8% tetralogy of Fallot (TOF); 11.6% congenital pulmonary stenosis (PS); 24.6% other diagnoses]. The overall median follow-up time was 9.1 years (interquartile range 5.3–12.6 years). The mean gradient was 11.8 ± 7.1 mmHg in PAV and 16.6 ± 9.6 mmHg in MFV patients. Congenital PS patients had 100% survival at 20 years, TOF patients at 5, 10, 15 and 20 years had 99%, 97%, 96% and 96% survival, respectively. Patients with other primary diagnoses at 5, 10, 15 and 20 years had 93%, 91%, 87% and 87% respectively. Freedom from reintervention did not differ significantly at 5 and 10 years between pulmonary allograft (98.6%, 98.6%) and Freestyle® porcine bioprosthesis (97.5%, 93%). CONCLUSIONS Both valves perform equally well with regard to patients’ freedom from reoperation, although transvalvular gradient was higher for Freestyle® patients. Congenital PS and TOF patients had better survival than patients with other primary diagnoses.

scholarly journals Long-Term Outcomes of Adults with Congenital Heart Disease Supported by Durable Continuous-Flow Ventricular Assist Devices

2021 ◽  
Vol 40 (4) ◽  
pp. S419-S420
Author(s):  
W.C. Frankel ◽  
C.R. Broda ◽  
A.P. Nair ◽  
W.J. Dreyer ◽  
H.P. Tunuguntla ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Continuous Flow ◽  
Congenital Heart ◽  
Ventricular Assist Devices ◽  
Long Term Outcomes ◽  
Ventricular Assist ◽  
Assist Devices

scholarly journals Implantable cardioverter defibrillators in adult congenital heart disease: long-term follow up of therapies, complications and clinical events

EP Europace ◽  
2021 ◽  
Vol 23 (Supplement_3) ◽  
Author(s):  
V Ferreira ◽  
M Cruz Coutinho ◽  
G Portugal ◽  
P Silva Cunha ◽  
B Valente ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Primary Prevention ◽  
Congenital Heart ◽  
Septal Defect ◽  
Long Term Outcomes ◽  
Icd Implantation ◽  
Heart Defect

Abstract Funding Acknowledgements Type of funding sources: None. Introduction Adults with congenital heart disease (ACHD) at increased risk for sudden cardiac death (SCD) often undergo implantable cardioverter defibrillator (ICD) implantation at young ages. Data evaluating the long-term outcomes of ICD in this population remain scarce. We aimed to characterize the population with ACHD and an ICD. Methods Consecutive ACHD submitted to an ICD implantation in a single tertiary center were evaluated. Data on baseline clinical features, heart defect, indication for ICD, type of device, ICD-related complication and therapies and mortality during follow-up were collected. Results A total of 34 patients (P) were evaluated. Median age at implant was 39.3 years (interquartile range [IQR] 29-5-53.6) and median left ventricular ejection fraction (LVEF) was 43.5% (IQR 28.0-53.3). The most common heart defect was tetralogy of Fallot (11P;32,3%), followed by dextro-transposition of the great arteries, ostium secundum atrial septal defect (ASD) and ventricular septal defect (Figure 1). All P were submitted to surgical correction (median age at surgery 12.5 years [IQR 3.0-29.1]). Sixteen P underwent ICD implantation for primary prevention of SCD, owing to complex cardiopathy and ventricular dysfunction, and 18P due to spontaneous ventricular tachyarrhythmias. The implantable devices were a single-chamber ICD in 55.9%, a double-chamber ICD in 17.6%, a subcutaneous ICD in 20.6% and a CRT-D in 5.9%. During a median follow-up of 4.5 years (IQR 2.1-8.8), 52.9% of the P received appropriate ICD therapies, corresponding to 37.5% and 66.7% of primary and secondary prevention P, respectively. Median time to first arrhythmic event was 25.3 months (IQR 13.7-52.9). Six P (17.6%) suffered ICD-related complications and 20.6% received inappropriate therapies due to supraventricular tachyarrhythmias. During follow-up, 8.8% were submitted to heart transplant and 29.4% died (Table 1).  ICD therapies were associated with a composite of death, cardiac transplantation and hospital admission (OR 5.0, 95% CI 1.0-24.3). Conclusion ACHD with ICD experience high rate of appropriate therapies, including those implanted for primary prevention. The long-term burden of ICD-related complications and inappropriate shocks underlines the need for careful risk stratification and close monitoring. The increased survival of this population justifies collecting data on long-term outcomes to improve its care. Abstract Figure.

scholarly journals Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease—a nationwide study

2020 ◽  
Author(s):  
Maria Fedchenko ◽  
Zacharias Mandalenakis ◽  
Kok Wai Giang ◽  
Annika Rosengren ◽  
Peter Eriksson ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Congenital Heart Disease ◽  
Heart Disease ◽  
Older Patients ◽  
Congenital Heart ◽  
Long Term Outcomes ◽  
Increased Risk ◽  
New Onset

Abstract Aims  We aimed to describe the risk of myocardial infarction (MI) in middle-aged and older patients with congenital heart disease (ACHD) and to evaluate the long-term outcomes after index MI in patients with ACHD compared with controls. Methods and results  A search of the Swedish National Patient Register identified 17 189 patients with ACHD (52.2% male) and 180 131 age- and sex-matched controls randomly selected from the general population who were born from 1930 to 1970 and were alive at 40 years of age; all followed up until December 2017 (mean follow-up 23.2 ± 11.0 years). Patients with ACHD had a 1.6-fold higher risk of MI compared with controls [hazard ratio (HR) 1.6, 95% confidence interval (CI) 1.5–1.7, P < 0.001] and the cumulative incidence of MI by 65 years of age was 7.4% in patients with ACHD vs. 4.4% in controls. Patients with ACHD had a 1.4-fold increased risk of experiencing a composite event after the index MI compared with controls (HR 1.4, 95% CI 1.3–1.6, P < 0.001), driven largely by the occurrence of new-onset heart failure in 42.2% (n = 537) of patients with ACHD vs. 29.5% (n = 2526) of controls. Conclusion  Patients with ACHD had an increased risk of developing MI and of recurrent MI, new-onset heart failure, or death after the index MI, compared with controls, mainly because of a higher incidence of newly diagnosed heart failure in patients with ACHD. Recognizing and managing the modifiable cardiovascular risk factors should be of importance to reduce morbidity and mortality in patients with ACHD.

scholarly journals Long-Term Outcomes of Children With Trisomy 13 and 18 After Congenital Heart Disease Interventions

2017 ◽  
Vol 103 (6) ◽  
pp. 1941-1949 ◽  
Author(s):  
Jennifer K. Peterson ◽  
Lazaros K. Kochilas ◽  
Kirsti G. Catton ◽  
James H. Moller ◽  
Shaun P. Setty
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Congenital Heart ◽  
Trisomy 13 ◽  
Long Term Outcomes

scholarly journals Long‐term outcomes of cardiac resynchronization therapy in adult congenital heart disease

2019 ◽  
Vol 42 (6) ◽  
pp. 573-580 ◽  
Author(s):  
Francisco Leyva ◽  
Abbasin Zegard ◽  
Tian Qiu ◽  
Joseph Bono ◽  
Sara Thorne ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Cardiac Resynchronization Therapy ◽  
Congenital Heart ◽  
Adult Congenital Heart Disease ◽  
Cardiac Resynchronization ◽  
Resynchronization Therapy ◽  
Long Term Outcomes ◽  
Adult Congenital

Abstract 17049: Outcomes of Bioprosthetic and Mechanical Aortic Valve Replacement in Patients With Congenital Heart Disease

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Reilly D Hobbs ◽  
Megan Schultz ◽  
Catherine Wagner ◽  
Richard G Ohye ◽  
Edward Bove ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Congenital Heart ◽  
Valve Repair ◽  
Long Term Outcomes ◽  
Long Term Mortality

Introduction: Aortic valve replacement (AVR) is required in patients with congenital heart disease who are not candidates for Ross procedure or valve repair. The long-term outcomes of prosthetic AVR in patients with congenital heart disease are unknown. Methods: A single-institution, retrospective review of all patients treated with mechanical (M) and bioprosthetic (BP) AVR between 12/1985 to 2/2020 was undertaken. Results: One-hundred and ninety-three patients underwent BP (n=134) or M (n=59) AVR. Indications for AVR were insufficiency (91/193), stenosis (61/194), mixed (38/193), aneurysm (2/193), and unknown (1/193). Patients receiving M valves were more likely to be younger (18.5 years versus 29.0 years, p < 0.01) and less likely to require subsequent valve reintervention (p < 0.01). Average time to first reintervention was 76 and 71 months in the BP and M groups respectively (p = 0.785). Survival between the M and BP groups was similar (p = 0.120). Twenty-four patients who received a M valve and thirteen patients who received a BP valve died during the study period. Causes of death were cardiac (16/37), stroke (3/37), non-cardiac (4/37), and unknown (14/37). Conclusions: Long-term freedom from death or valve reintervention is poor in congenital heart disease patients requiring AVR. Survival is similar between patients treated with M and BP valves, however, BP valves more frequently required reintervention during the study period. Both BP and M valves are associated with significant long-term mortality. These results highlight the need for the development of robust aortic valve repair techniques so that AVR can be avoided.

Sign in / Sign up

Export Citation Format

Share Document